Scott Claunch, RPh, has joined TerraPower as President of Medical Isotopes, leading a division of the company focused on next-generation therapeutic medical isotopes for Targeted Alpha Therapy (TAT) treatments. In this role, he oversees TerraPower’s team focused on separating and processing Thorium-229 into Actinium-225, which may improve cancer treatments by destroying targeted cancer cells with minimum damage to healthy cells.
“We are excited to welcome Scott to our TerraPower team as we continue to advance applications of nuclear technology to improve cancer treatments,” said Chris Levesque, TerraPower President and CEO. “Scott brings his unique background and expertise to our medical isotopes work and our efforts to realize the full potential of nuclear science.”
Scott has more than 25 years of experience in nuclear medicine. He joins TerraPower from the Global Nuclear Medicine Franchise at Lantheus Medical Imaging. At Lantheus, Scott was responsible for commercial sales of nuclear medicine products and pre-launch activities for the company’s future portfolio in Positron Emission Tomography. He also oversaw cyclotron operations used in the manufacture and distribution of radiopharmaceuticals globally.
Previously, Scott held various leadership positions in operations, change management, quality and sourcing at Option Care Health and Cardinal Health Nuclear Pharmacy Services.
“The opportunity to join TerraPower’s groundbreaking work in bringing Actinium-225 to those working on new drug development is exciting,” Scott said. “My career has been spent in elevating the potential of drug therapies to save lives and Actinium-225 has the potential to transform cancer treatment.”
Scott remains active as a nuclear pharmacist and previously served as a board member for the Alzheimer’s Association, Central Ohio Chapter. He earned a bachelor’s degree in pharmacy, specializing in nuclear pharmacy, from the University of New Mexico.
